openPR Logo
Press release

Benign Prostatic Hyperplasia (BPH) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top players are Sanofi, Pfizer, Astellas Pharma US, Eli Lilly and Company, Merck, GSK, Allergan, Veru Inc., Urova

06-06-2019 01:35 PM CET | Health & Medicine

Press release from: Pharma Proff

Benign Prostatic Hyperplasia (BPH) Therapeutics Pipeline

BPH can be identified as enlargement of prostate gland, a condition affects majority of male population. It is non-cancerous and goes through two main growth periods as a man age. The first phase begins in puberty, when the size of prostate becomes double. The second phase of prostate growth normally begins in the second decade of life. It is observed that men with a family history of BPH and chronic diseases such as heart disease, obesity, and diabetes are at higher risk of developing BPH. The condition thickens bladder wall, and eventually the bladder may weaken and lose the ability to empty completely. BPH is also associated with complications of urinary tract infection, bladder stones, kidney damage, and constant urge to urinate. The root cause of the disease remains unknown; however, increased level of estrogen is a suspected reason for the occurrence of this disease.

Download the sample report at:

BPH can be diagnosed through physical examinations and medical tests, including digital rectal exam, urine test, blood test, prostate-specific antigen (PSA) test, and others. In severe cases, transrectal ultrasound, prostate biopsy, and cystoscopy are also performed. Uroxatral (Sanofi), Cardura (Pfizer Inc.), Flomax (Astellas Pharma Inc.), Proscar (Merck & Co. Inc.), Avodart (GlaxoSmithKline plc), Jalyn (GlaxoSmithKline plc), Cialis (Eli Lilly and Company), Hytrin (Abbott Laboratories), and Rapaflo (Allergan plc) are approved drugs available for the treatment of BPH.

Browse Detailed Report at:

It has been observed during the research that majority of the drugs are designed as either alpha blockers or 5-alpha reductase inhibitors. Alpha-blockers primarily relax the bladder and prostate muscles; while, 5-alpha reductase inhibitors prevent further growth of prostate and help in shrinking it to relieve symptoms.

Companies that are involved in developing therapeutics for BPH have shown positive clinical results in various phases of drug development. For instance, in January 2018, Nymox Pharmaceutical Corporation reported positive outcomes from the Phase III clinical study of fexapotide triflutate. According to the results, fexapotide demonstrated significant long-term benefit for BPH.

Make enquiry before purchase at:

It has been observed that many pharmaceutical companies are entering into acquisitions for the development of BPH therapeutics and their geographical expansion. For instance, Boston Scientific Corporation announced the acquisition of NxThera Incorporated. Through this acquisition, Boston Scientific Corporation is likely to increase its BPH therapeutics portfolio.

Moreover, Sanofi, Abbott Laboratories, Pfizer Inc., Astellas Pharma Inc., Eli Lilly and Company, Merck & Co. Inc., Nymox Pharmaceutical Corporation, GlaxoSmithKline plc, Allergan plc, Veru Inc., Urovant Sciences Inc., and Caremark Limited are some of the key players involved in the development of therapeutic agents for BPH.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Benign Prostatic Hyperplasia (BPH) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top players are Sanofi, Pfizer, Astellas Pharma US, Eli Lilly and Company, Merck, GSK, Allergan, Veru Inc., Urova here

News-ID: 1766733 • Views: 1797

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases

More Releases for BPH

Elderly Men Creating Huge Requirement for BPH Treatment Drugs and Devices
Benign prostatic hyperplasia (BPH) or prostate gland enlargement is caused due to urinary tract infections, bladder or kidney stones, prostatitis, urethral stricture, bladder or prostate cancer, and scarring in the bladder neck caused due to previous surgeries. The common signs and symptoms of BPH include frequent urination, nocturia, difficulty in initiating urination, dribble at the end of urination, and inability to empty the bladder. This disease is highly prevalent among
Benign prostatic hyperplasia: BPH drugs versus Dr Allen’s Device
The Global Treatment Market of Benign prostatic hyperplasia (BPH) was valued at $10,688.72 million in 2017 and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025. Thermobalancing therapy with Dr Allen’s Device was patented by the United States Patent and Trademark Office. Over a decade, thousands of men with BPH used or are using this non-invasive and side-effects free Dr Allen’s Device.
Benign Prostatic Hyperplasia (BPH) Procedures Insights, Potential Business Strat …
Increasing life expectancy and fall in the birth rates are the major reasons for rise in the aging population. The people in this category require extensive care, since they are more prone to illness due to low immunity levels and longer recovery time. Increase in the aging population in the U.S., Germany, China and India in the next few years, is expected to create high demand for BPH treatment devices,
Benign Prostatic Hyperplasia (BPH) Treatment Devices Market Trends, Technologica …
Benign Prostatic Hyperplasia (BPH) refers to an enlarged prostate gland. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Enlargement of prostate gland leads to blockage in urethra, thus causing problems during urination. It involves glandular and stromal epithelial hyperplasia, which occurs in the peri-urethral transition zone surrounding the urethra. Access Detailed Report Summary: BPH is common in aging men,
Benign Prostatic Hyperplasia (BPH) And Prostate Treatment Market Industry Trends …
Benign prostatic hyperplasia (BPH) is also known as benign prostatic hypertrophy or benign prostatic obstruction. Benign prostatic hyperplasia (BPH) is a health condition in men in which the prostate gland size is enlarged than a normal. In a men whole life, prostate grows in two phases, first phase is occurs in early stage of puberty, second phase starts at the age of twenty five and it continues most of persons
US Benign Prostatic Hyperplasia (BPH) Procedures - Development, Growth and Forec …
Increase in the aging population in the U.S in the next few years, is expected to create high demand for BPH treatments, since the population aged 50 years and above is more prone to BPH, and therefore tend to opt for various treatments that involve the use of procedures such as TURP, TUIP and laser based treatments. According to the National Institute of Health, it has been estimated that around